Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company`s lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia`s Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Website: cel-sci.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 38.2% (LTM)

Entry Point: Share price is 52.3% higher than minimum and 93.5% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: CVM
Share price, USD:  (+10.1%)1.63
year average price 2.0416  


year start price 2.4300 2023-05-06

min close price 1.0700 2023-10-20

max close price 3.0800 2024-02-06

current price 1.6300 2024-05-04
Common stocks: 43 328 100

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 71
Net Debt ($m): -33
EV (Enterprise Value): 38
Price to Book: 5.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-07-18InvestorPlace

Why Is CEL-SCI (CVM) Stock Down 23% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CVM CVM CVM CVM CVM CVM
reportedCurrency USD USD USD USD USD USD
cik 725 363 725 363 725 363 725 363 725 363 725 363
fillingDate 2024-02-14 2023-12-21 2023-08-10 2023-05-12 2023-02-14 2022-12-27
acceptedDate 2024-02-14 16:31:12 2023-12-21 16:15:39 2023-08-10 16:10:28 2023-05-12 16:11:55 2023-02-14 16:16:36 2022-12-27 16:15:57
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4
revenue 0 0 0 0 0 0
costOfRevenue 1M 998 653 0 0 0 0
grossProfit -1M -998 653 0 0 0 0
grossProfitRatio 0 0 0 0 0 0
researchAndDevelopmentExpenses 4M 5M 6M 6M 5M 6M
generalAndAdministrativeExpenses 2M 2M 2M 2M 2M 2M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 2M 2M 2M 2M 2M
otherExpenses -25 941 18 712 -3854.000 -7500.000 -50 171 0
operatingExpenses 6M 7M 8M 8M 8M 9M
costAndExpenses 6M 7M 8M 8M 8M 9M
interestIncome 0 181.894 0 0 0 0
interestExpense 197 696 181 894 181 670 159 063 152 789 -379 021
depreciationAndAmortization 1M 998 653 985 699 977 939 938 372 1M
ebitda -6M -6M -7M -7M -7M -8M
ebitdaratio 0 0 0 0 0 0
operatingIncome -6M -7M -8M -8M -8M -9M
operatingIncomeRatio 0 0 0 0 0 0
totalOtherIncomeExpensesNet -25 941 18 712 -3854.000 -166 563 -374 512 486 169
incomeBeforeTax -7M -8M -8M -8M -8M -8M
incomeBeforeTaxRatio 0 0 0 0 0 0
incomeTaxExpense 171 755 200 606 177 816 166 563 374 512 442 953
netIncome -7M -8M -8M -9M -8M -9M
netIncomeRatio 0 0 0 0 0 0
eps -0.140 -0.160 -0.190 -0.200 -0.190 -0.210
epsdiluted -0.140 -0.160 -0.190 -0.200 -0.190 -0.210
weightedAverageShsOut 48M 47M 44M 44M 43M 43M
weightedAverageShsOutDil 48M 47M 44M 44M 44M 43M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CVM CVM CVM CVM CVM CVM
reportedCurrency USD USD USD USD USD USD
cik 725 363 725 363 725 363 725 363 725 363 725 363
fillingDate 2024-02-14 2023-12-21 2023-08-10 2023-05-12 2023-02-14 2022-12-27
acceptedDate 2024-02-14 16:31:12 2023-12-21 16:15:39 2023-08-10 16:10:28 2023-05-12 16:11:55 2023-02-14 16:16:36 2022-12-27 16:15:57
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4
cashAndCashEquivalents 3M 4M 5M 10M 18M 23M
shortTermInvestments 16.129 4.245 0 0 0 0
cashAndShortTermInvestments 3M 4M 5M 10M 18M 23M
netReceivables -2M 0 -2M -2M -2M 0
inventory 2M 2M 2M 2M 2M 2M
otherCurrentAssets 3M 524 613 3M 3M 2M 3M
totalCurrentAssets 6M 7M 8M 13M 20M 25M
propertyPlantEquipmentNet 20M 21M 22M 23M 24M 25M
goodwill 0 0 0 0 0 0
intangibleAssets 188 294 197 704 183 074 192 231 202 070 212 201
goodwillAndIntangibleAssets 188 294 197 704 183 074 192 231 202 070 212 201
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 2M 2M 2M 2M 104 607 164 299
totalNonCurrentAssets 23M 24M 25M 26M 24M 25M
otherAssets -0.000 0 0 0 0 0
totalAssets 29M 31M 32M 38M 45M 51M
accountPayables 1M 2M 2M 2M 2M 2M
shortTermDebt 2M 2M 2M 2M 2M 2M
taxPayables 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0
otherCurrentLiabilities 2M 2M 2M 2M 1M 1M
totalCurrentLiabilities 5M 6M 5M 5M 5M 5M
longTermDebt 11M 12M 12M 13M 13M 14M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 125 000 125 000 125 000 125 000 125 000 10M
totalNonCurrentLiabilities 11M 12M 12M 13M 13M 14M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 13M 14M 14M 14M 15M 15M
totalLiabilities 16M 17M 18M 18M 18M 18M
preferredStock 0 0 0 0 0 0
commonStock 500 186 474 223 447 484 437 878 437 256 434 484
retainedEarnings -494M -487M -479M -471M -463M -455M
accumulatedOtherComprehensiveIncomeLoss 0.000 -0.000 0 0 0 0
othertotalStockholdersEquity 506M 500M 494M 491M 489M 487M
totalStockholdersEquity 13M 13M 15M 20M 27M 32M
totalEquity 13M 13M 15M 20M 27M 32M
totalLiabilitiesAndStockholdersEquity 29M 31M 32M 38M 45M 51M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 29M 31M 32M 38M 45M 51M
totalInvestments 16.129 4.245 0 0 0 0
totalDebt 13M 14M 14M 14M 15M 15M
netDebt 10M 9M 9M 4M -3M -7M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CVM CVM CVM CVM CVM CVM
reportedCurrency USD USD USD USD USD USD
cik 725 363 725 363 725 363 725 363 725 363 725 363
fillingDate 2024-02-14 2023-12-21 2023-08-10 2023-05-12 2023-02-14 2022-12-27
acceptedDate 2024-02-14 16:31:12 2023-12-21 16:15:39 2023-08-10 16:10:28 2023-05-12 16:11:55 2023-02-14 16:16:36 2022-12-27 16:15:57
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4
netIncome -7M -8M -8M -8M -8M -8M
depreciationAndAmortization 1M 998 653 985 699 985 439 988 543 982 939
deferredIncomeTax 0 0 0 0 0 0
stockBasedCompensation 2M 2M 2M 2M 2M 2M
changeInWorkingCapital -836 743 42 986 -68 521 -2M 301 372 643 548
accountsReceivables 0 0 0 0 0 0
inventory -98 765 -132 236 -194 925 -42 253 212 687 7023.000
accountsPayables -765 078 191 229 -36 225 218 126 -115 285 785 426
otherWorkingCapital 27 100 -16 007 162 629 -2M 203 970 -148 901
otherNonCashItems 2504.000 2504.000 3243.000 -144 391 153 936 182 017
netCashProvidedByOperatingActivities -5M -5M -6M -7M -5M -5M
investmentsInPropertyPlantAndEquipment -64 861 -10 370 -196 860 -111 452 -53 580 -16 066
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites -13.211 -10.370 0 0 0 0
netCashUsedForInvestingActivites -64 861 -10 370 -196 860 -111 452 -53 580 -16 066
debtRepayment -426 593 -403 084 -396 148 -388 352 -372 871 -352 818
commonStockIssued 5M 5M 0 0 -9010.000 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -504 913 -691 717 1M 0 447 291 -118 930
netCashUsedProvidedByFinancingActivities 4M 4M 951 563 -388 352 65 410 -471 748
effectOfForexChangesOnCash 0 0 0 0 0 0
netChangeInCash -904 295 -989 335 -5M -8M -5M -5M
cashAtEndOfPeriod 3M 4M 5M 10M 18M 23M
cashAtBeginningOfPeriod 4M 5M 10M 18M 23M 28M
operatingCashFlow -5M -5M -6M -7M -5M -5M
capitalExpenditure -64 861 -10 370 -196 860 -111 452 -53 580 -16 066
freeCashFlow -5M -5M -6M -8M -5M -5M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-02-15 13:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
2024-02-13 17:00 ET
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
2024-02-09 13:30 ET
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
2024-02-06 14:00 ET
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
2024-01-31 14:00 ET
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
2023-12-22 13:00 ET
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
2023-12-04 13:30 ET
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
2023-11-20 21:15 ET
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
2023-11-16 13:30 ET
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
2023-10-30 13:20 ET
CEL-SCI Issues Letter to Shareholders
2023-10-24 12:00 ET
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
2023-10-23 13:15 ET
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
2023-10-19 12:00 ET
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
2023-10-05 12:45 ET
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
2023-09-26 13:00 ET
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
2023-08-11 12:00 ET
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
2023-07-20 15:36 ET
CEL-SCI Announces Closing of Public Offering
2023-07-18 01:23 ET
CEL-SCI Announces Pricing of Public Offering
2023-07-17 20:05 ET
CEL-SCI Announces Proposed Public Offering of Common Stock
2023-07-14 13:15 ET
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
2023-07-11 12:45 ET
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
2023-06-22 14:19 ET
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
2023-05-15 13:00 ET
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
2023-05-12 20:30 ET
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
2023-04-28 01:12 ET
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
2023-04-19 13:00 ET
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
2023-03-08 14:00 ET
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
2023-03-03 14:00 ET
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
2023-02-15 14:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
2022-12-28 14:00 ET
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
2022-11-22 14:00 ET
CEL-SCI Corporation Issues Letter to Shareholders
2022-10-17 12:50 ET
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
2022-09-12 13:00 ET
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
2022-09-07 12:45 ET
CEL-SCI Corporation Issues Letter to Shareholders
2022-08-19 12:45 ET
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
2022-08-15 13:00 ET
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
2022-08-08 12:45 ET
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
2022-07-14 14:00 ET
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
2022-06-08 13:00 ET
CEL-SCI Corporation to Present at LD Micro Invitational
2022-06-07 11:30 ET
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
2022-05-27 13:00 ET
CEL-SCI Announces Publication of ASCO 2022 Abstracts
2022-05-16 12:50 ET
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
2022-04-22 13:21 ET
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
2022-02-14 14:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
2021-12-22 14:00 ET
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
2021-10-22 12:00 ET
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
2021-08-16 13:00 ET
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
2021-07-07 12:00 ET
CEL-SCI Corporation Issues Letter to Shareholders
2021-07-02 15:20 ET
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available
2021-06-30 13:00 ET
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
2021-06-28 13:20 ET
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
2021-06-25 12:30 ET
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
2021-06-11 15:49 ET
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
2021-06-09 01:03 ET
CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million
2021-06-08 20:37 ET
CEL-SCI Announces Bought Deal Offering
2021-05-18 13:00 ET
CEL-SCI Corporation Reports Second Quarter Fiscal 2021 Financial Results
2021-02-16 14:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results
2021-01-08 13:30 ET
CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference
2021-01-04 14:15 ET
CEL-SCI Corporation Issues Letter to Shareholders
2020-12-30 13:00 ET
CEL-SCI Reports Fiscal 2020 Financial Results and Clinical & Corporate Developments
2020-12-14 13:30 ET
CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference
2020-12-11 16:29 ET
CEL-SCI Announces the Closing of Its $14.65 Million Bought Deal
2020-12-08 23:44 ET
CEL-SCI Announces Bought Deal Offering
2020-12-07 14:15 ET
CEL-SCI Announces Update on Phase 3 Cancer Trial Results
2020-12-01 14:00 ET
CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies
2020-09-18 13:00 ET
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
2020-09-15 13:15 ET
CEL-SCI Corporation Issues Letter to Shareholders
2020-09-11 13:00 ET
CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference
2020-08-31 13:00 ET
CEL-SCI Corporation to Present at The LD 500 Virtual Conference
2020-08-11 12:30 ET
CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results
2020-07-24 12:30 ET
CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment
2020-06-30 12:30 ET
CEL-SCI Corporation Receives $10 Million Through Warrant Exercises
2020-06-24 14:00 ET
CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series
2020-05-11 12:00 ET
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results
2020-05-04 11:15 ET
CEL-SCI’s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of Head and Neck Cancer
2020-04-23 13:15 ET
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
2020-04-08 12:00 ET
Important Update For CEL-SCI Corporation Annual Meeting of Shareholders
2020-03-30 20:05 ET
CEL-SCI Announces Change of Location to 2020 Annual Meeting of Shareholders
2020-03-26 15:05 ET
CEL-SCI Announces the Closing of Its $7.7 Million Bought Deal
2020-03-24 13:25 ET
CEL-SCI Increases Previously Announced Bought Deal to $7.7 Million
2020-03-24 01:46 ET
CEL-SCI Announces Bought Deal Offering
2020-03-23 13:00 ET
CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center for Vaccines and Immunology
2020-03-09 11:55 ET
CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19 Coronavirus Infection
2020-02-26 20:19 ET
CEL-SCI Corporation Issues Letter to Shareholders
2020-02-10 13:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2020 Financial Results
2020-02-06 14:00 ET
CEL-SCI to Present at 2020 BIO CEO & Investor Conference
2020-01-10 13:30 ET
CEL-SCI to Participate in Upcoming Investor Conferences
2020-01-07 19:40 ET
CEL-SCI Announces Full Exercise of Over-allotment Option by Aegis Capital Corp.
2019-12-27 16:15 ET
CEL-SCI Announces the Closing of Its $5.5 Million Underwritten Offering
2019-12-24 12:16 ET
CEL-SCI Prices $5.5 Million Underwritten Public Offering of Common Stock
2019-12-23 21:04 ET
CEL-SCI Announces Proposed Underwritten Public Offering of Common Stock
2019-12-16 21:15 ET
CEL-SCI Reports Fiscal 2019 Financial Results and Clinical & Corporate Developments
2019-12-06 14:00 ET
CEL-SCI Corporation to Present at The LD Micro Main Event (XII)

SEC forms

Show financial reports only

SEC form 10
2024-02-14 00:00 ET
CEL-SCI Corporation reported for 2023 q4
SEC form 10
2023-12-21 16:15 ET
CEL-SCI Corporation reported for 2023 q3
SEC form 10
2023-12-21 00:00 ET
CEL-SCI Corporation reported for 2023 q3
SEC form 10
2023-08-10 16:10 ET
CEL-SCI Corporation reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
CEL-SCI Corporation reported for 2023 q2
SEC form 6
2023-07-20 16:10 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 6
2023-07-18 16:05 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 6
2023-07-14 12:25 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 6
2023-07-12 09:01 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 10
2023-05-12 16:11 ET
CEL-SCI Corporation reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
CEL-SCI Corporation reported for 2023 q1
SEC form 6
2023-05-02 16:39 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-05-01 16:15 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-04-19 10:56 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-04-10 10:01 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-04-10 10:00 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-03-09 10:09 ET
CEL-SCI Corporation published news for 2022 q4
SEC form 10
2023-02-14 16:16 ET
CEL-SCI Corporation reported for 2022 q4
SEC form 10
2023-02-14 00:00 ET
CEL-SCI Corporation reported for 2022 q4
SEC form 10
2022-12-27 16:15 ET
CEL-SCI Corporation reported for 2022 q3
SEC form 10
2022-12-27 00:00 ET
CEL-SCI Corporation reported for 2022 q3
SEC form 6
2022-09-13 11:23 ET
CEL-SCI Corporation published news for 2022 q2
SEC form 6
2022-08-22 09:00 ET
CEL-SCI Corporation published news for 2022 q2
SEC form 10
2022-08-12 16:17 ET
CEL-SCI Corporation reported for 2022 q2
SEC form 10
2022-08-12 00:00 ET
CEL-SCI Corporation reported for 2022 q2
SEC form 6
2022-08-08 16:06 ET
CEL-SCI Corporation published news for 2022 q2
SEC form 6
2022-06-13 17:02 ET
CEL-SCI Corporation published news for 2022 q1
SEC form 10
2022-05-13 16:16 ET
CEL-SCI Corporation reported for 2022 q1
SEC form 10
2022-05-13 00:00 ET
CEL-SCI Corporation reported for 2022 q1
SEC form 6
2022-04-29 16:08 ET
CEL-SCI Corporation published news for 2022 q1
SEC form 6
2022-04-29 16:06 ET
CEL-SCI Corporation published news for 2022 q1
SEC form 10
2022-02-11 16:16 ET
CEL-SCI Corporation published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
CEL-SCI Corporation published news for 2021 q4
SEC form 10
2021-12-21 16:33 ET
CEL-SCI Corporation published news for 2021 q3
SEC form 10
2021-12-21 00:00 ET
CEL-SCI Corporation published news for 2021 q3
SEC form 10
2021-08-13 16:17 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 10
2021-08-13 00:00 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 6
2021-07-07 15:24 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 6
2021-07-01 17:43 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 6
2021-06-29 08:29 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 6
2021-06-09 16:09 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 6
2021-05-18 11:02 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 6
2021-05-18 11:00 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 10
2021-05-17 16:11 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 10
2021-02-12 16:16 ET
CEL-SCI Corporation published news for 2020 q4
SEC form 6
2020-12-30 17:36 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-30 17:17 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-30 17:16 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 10
2020-12-29 17:01 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-29 17:00 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-09 17:05 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-07 18:00 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-10-30 16:17 ET
CEL-SCI Corporation published news for 2020 q3